Filing Details

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

This Amendment No. 1 (“Amendment No. 1”) to Schedule 13D relates to the common stock, par value $0.0001 per share (“Shares”), of Kymera Therapeutics, Inc., a Delaware corporation (“Issuer” or “Kymera”), and amends and supplements the initial statement on Schedule 13D filed on September 3, 2020 (as amended, the “Schedule 13D”). Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used but not defined in this Amendment No. 1 shall have the same meanings ascribed to them in the Schedule 13D.

Item 2. Identity and Background

Item 2 of the Schedule 13D is hereby amended by incorporating herein by reference the information set forth on the updated Schedule A attached hereto.

Item 5. Interest in Securities of Issuer

Item 5 of the Schedule 13D is hereby amended and restated as follows:

(a) As of the date hereof, Vertex does not beneficially own any Shares. To the knowledge of Vertex, no director or executive officer of Vertex beneficially owns any Shares.

(b) Not applicable.

(c) On June 1, 2023, Vertex sold 3,533,899 Shares in a block trade to a third party financial institution at a price of $26.92 per share. Except for the transactions described in this Amendment No. 1, Vertex has not entered into any transactions in the Shares during the past sixty days.

(d) Not applicable.

(e) As of June 1, 2023, Vertex ceased to beneficially own more than five percent of the outstanding Shares.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

[Signature Page to Schedule 13D/A]

SCHEDULE A

The name, business address and present principal occupation or employment of each of the directors and executive officers of Vertex are set forth below. The business address of each director and executive officer is c/o Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210. Each director and executive officer is a citizen of the United States, except for Dr. Bozic who is a citizen of Canada. Mr. Arbuckle is also a citizen of the United Kingdom and Dr. Sanna is also a citizen of Italy.